XML 71 R58.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders’ Equity and Stock-Based Compensation (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 27, 2023
Mar. 05, 2021
Jan. 27, 2023
Dec. 31, 2020
Sep. 24, 2022
Jun. 25, 2022
Sep. 25, 2021
Jun. 26, 2021
Mar. 27, 2021
Mar. 26, 2021
Dec. 31, 2022
Dec. 25, 2021
Dec. 26, 2020
Sep. 26, 2021
Subsidiary, Sale of Stock [Line Items]                            
Proceeds from sale of common stock     $ 17,000,000                      
Common Stock, Shares Authorized                     150,000,000 150,000,000    
Number of shares, restricted stock granted                     1,013,600 2,247,343    
Stock-based compensation                     $ 1,267,705 $ 4,417,422 $ 821,122  
Unrecognized compensation expense                     $ 4,400,000      
Weighted average period, unrecognized                     4 years      
2020 Equity Incentive Plan [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Number of shares authorized to issue                         4,000,000  
Common Stock, Shares Authorized                         10,000,000  
Number of shares available for grant                     7,100,000      
Vesting period description                     the Company for periods ranging from one to five years (the vesting period)      
Subsequent Event [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Number of common stock sold, shares 17,000,000                          
Pre-funded warrants issued to purchase common stock 6,000,000   6,000,000                      
Offering price per share $ 0.99   $ 0.99                      
Subsequent Event [Member] | Prefunded Warrants [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Underwriting discounts and offering expenses $ 1,500,000                          
Pre-funded warrants issued to purchase common stock 6,000,000   6,000,000                      
Offering price per share $ 0.99   $ 0.99                      
roceeds from issuance of warrants $ 22,900,000                          
Exercise price of warrants $ 0.01   $ 0.01                      
Employment Agreement [Member] | Dr. John Fan [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Number of shares, restricted stock granted       188,000                    
Stock-based compensation       $ 2,100,000                    
At The Market Offering [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Number of common stock sold, shares                     126,389      
Underwriting discounts and offering expenses         $ 100,000   $ 100,000 $ 100,000   $ 500,000        
Proceeds from sale of common stock                     $ 200,000      
Commissions paid                     10,000      
At The Market Offering [Member] | Common Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Number of common stock sold, shares         675,000 1,500,000 600,000 100,000 2,400,000          
Gross proceeds from registered sale equity securities         $ 900,000 $ 2,100,000 $ 4,800,000 $ 800,000 $ 16,000,000          
Share price         $ 1.27 $ 1.26   $ 6.74 $ 6.66         $ 8.06
Underwriting discounts and offering expenses                     $ 41,400,000      
At The Market Offering [Member] | Common Stock [Member] | Maximum [Member] | Stifel [Member] | March 5, 2021 At The Market Agreement [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Proceeds from sale of common stock   $ 50,000,000                        
At The Market Offering [Member] | Treasury Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Number of common stock sold, shares           200,000